Effect of Haemodialysis on the Efficacy of Antiplatelet Agents
NCT03330223 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2018-01-08
Summary
The main purpose of our study is to investigate whether haemodialysis itself affects the efficacy of antiplatelet drugs and the effects of two different types of dialysis membranes (polysulfone membranes and polyamide membranes) on antiplatelet efficacy. A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after two times of haemodialysis.
Conditions
- Renal Failure
- Coronary Artery Disease
- Hemolysis
Interventions
- DEVICE
-
Clopidogrel group;Ticagrelor group
A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.
Sponsors & Collaborators
-
The First Affiliated Hospital with Nanjing Medical University
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-11-10
- Primary Completion
- 2019-04-20
- Completion
- 2019-09-01
Countries
- China
Study Locations
More Related Trials
-
Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
NCT01511471 ·Status: COMPLETED ·Phase: PHASE3
-
Genotype and Platelet Reactivity in Patients on Hemodialysis
NCT02394145 ·Status: UNKNOWN ·Phase: PHASE3
-
Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
NCT03774394 ·Status: COMPLETED ·Phase: PHASE4
-
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.
NCT03357874 ·Status: COMPLETED ·Phase: PHASE3
-
Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD
NCT03614832 ·Status: UNKNOWN ·Phase: PHASE4
-
Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients
NCT02459288 ·Status: UNKNOWN ·Phase: PHASE4
-
Platelet Reactivity in Acute Non-disabling Cerebrovascular Events
NCT02506140 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS
NCT02578537 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease
NCT01328470 ·Status: COMPLETED ·Phase: PHASE4
-
A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting
NCT02330640 ·Status: COMPLETED ·Phase: PHASE4
-
Platelet Reactivity After Receiving Clopidogrel Among Moderate CKD Patients Undergoing PCI
NCT02556671 ·Status: UNKNOWN
-
Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients
NCT01865890 ·Status: COMPLETED
-
Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI
NCT03078465 ·Status: WITHDRAWN ·Phase: PHASE3
-
Impact of Renal Function on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients
NCT02323971 ·Status: UNKNOWN
-
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis
NCT01155765 ·Status: COMPLETED ·Phase: PHASE3
-
Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI
NCT03381755 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products
NCT02010632 ·Status: COMPLETED ·Phase: PHASE1
-
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
NCT02287909 ·Status: COMPLETED ·Phase: PHASE4
-
Clopidogrel And Ticagrelor in Healthy Subjects
NCT02086903 ·Status: COMPLETED ·Phase: PHASE3
-
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease
NCT04001894 ·Status: COMPLETED ·Phase: PHASE4
-
Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
NCT01823185 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparison Of Efficacy and Safety Between Ticagrelor and Clopidogrel In Chinese
NCT03239067 ·Status: COMPLETED
-
Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation
NCT02379676 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting
NCT00661206 ·Status: UNKNOWN ·Phase: PHASE4
-
Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients
NCT01779401 ·Status: COMPLETED ·Phase: NA